|
|
|
 |
 |
|
       |
|
|
|
Licensing | Thrombospondin-1  In most cancers, the growth of malignant tumors is dependent upon the development of new blood vessels, or angiogenesis, to provide sufficient blood flow. Tumors achieve this blood vessel growth, or neovascularization, by producing angiogenic factors such as VEGF (Vascular Endothelial Growth Factor) and TGFB (Tumor Growth Factor Beta). Likewise, in healthy tissues neovascularization is held in check by naturally occurring anti-angiogenic factors such as Thrombospondin-1 (TSP-1). TSP-1 is a potent inhibitor of angiogenesis and effectively inhibits a wide variety of angiogenic stimuli, including VEGF, proteins that act via tyrosine kinase receptors, G proteins, serine/threonine kinase receptors and lipids. Protein Sciences holds an exclusive worldwide commercial license to an issued patent for the use of TSP-1 for the inhibition of angiogenesis (U.S. 5,192,744 issued March 9, 1993). The company is currently discussing the initiation of clinical trials for various indications with Northwestern University and with Brown University Cancer Center and seeks partnerships for the clinical development, distribution and marketing of this compound. For more information, please contact Manon Cox, Vice President, Chief Operating Officer. |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
